Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | STAT3 | P40763 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | RHEB | Q15382 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5521439 | 0.85 | MAPT (0.50) | MAPTHTTSMN1; SMN2STAT3LMNA | |
| SCHEMBL5036061 | 0.79 | NCF1 (0.54) | HTTSMN1; SMN2STAT3LMNAMAPK1 | |
| SCHEMBL6872247 | 0.79 | MAPT (0.44) | MAPTHTTSMN1; SMN2STAT3LMNA | |
| SCHEMBL3646897 | 0.79 | MAPT (0.55) | MAPTSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL27586264 | 0.78 | SMN1; SMN2 (0.39) | MAPTHTTSMN1; SMN2STAT3LMNA | |
| SCHEMBL5033238 | 0.78 | MAPT (0.54) | MAPTLMNATDP1 | |
| SCHEMBL18497724 | 0.78 | MAPT (0.45) | MAPTHTTSMN1; SMN2STAT3RHEB | |
| SCHEMBL18497755 | 0.77 | CNR1 (0.45) | MAPTSMN1; SMN2POLB | |
| SCHEMBL3427699 | 0.76 | ENPP1 (0.45) | MAPTHTTSMN1; SMN2STAT3LMNA | |
| SCHEMBL18587382 | 0.76 | MAPT (0.49) | MAPTHTTSMN1; SMN2STAT3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100376557-C | Quinoline derivatives as ligands for neuropeptide Y receptors | HOFFMANN LA ROCHE (CH) | 2008-03-26 | — | — | CN | disclosed |
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| CN-1522249-A | Quinoline derivatives as ligands for neuropeptide Y receptors | — | 2004-08-18 | — | — | CN | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAPT 3753/4885HTT 224/4885SMN1; SMN2 4211/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAPT 3753/4885HTT 224/4885SMN1; SMN2 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.